S.2465 - Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2018115th Congress (2017-2018)
|Sponsor:||Sen. Scott, Tim [R-SC] (Introduced 02/28/2018)|
|Committees:||Senate - Health, Education, Labor, and Pensions|
|Latest Action:||12/18/2018 Became Public Law No: 115-327. (All Actions)|
This bill has the status Became Law
Here are the steps for Status of Legislation:
- Passed Senate
- Passed House
- To President
- Became Law
Text: S.2465 — 115th Congress (2017-2018)All Information (Except Text)
Text available as:
AT THE SECOND SESSION
Begun and held at the City of Washington on Wednesday,
the third day of January, two thousand and eighteen
To amend the Public Health Service Act to reauthorize a sickle cell disease prevention and treatment demonstration program and to provide for sickle cell disease research, surveillance, prevention, and treatment.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
This Act may be cited as the “Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2018”.
Part A of title XI of the Public Health Service Act is amended by inserting after section 1105 (42 U.S.C. 300b–4) the following:
“(i) improving national incidence and prevalence data;
“(ii) identifying health disparities, including the geographic distribution, related to such diseases and conditions;
“(iii) assessing the utilization of therapies and strategies to prevent complications; and
“(iv) evaluating the effects of genetic, environmental, behavioral, and other risk factors that may affect such individuals.
“(i) developing strategies to improve health outcomes and access to quality health care for the screening for, and treatment and management of, such diseases and conditions, including through public-private partnerships;
“(ii) providing support to community-based organizations and State and local health departments in conducting education and training activities for patients, communities, and health care providers concerning such diseases and conditions;
“(iii) supporting State health departments and regional laboratories, including through training, in testing to identify such diseases and conditions, including specific forms of sickle cell disease, in individuals of all ages; and
“(iv) the identification and evaluation of best practices for treatment of such diseases and conditions, and prevention and management of their related complications.
“(2) POPULATION INCLUDED.—The Secretary shall, to the extent practicable, award grants under this subsection to eligible entities across the United States to improve data on the incidence and prevalence of heritable blood disorders, including sickle cell disease, and the geographic distribution of such diseases and conditions.
“(3) APPLICATION.—To seek a grant under this subsection, an eligible entity shall submit an application to the Secretary at such time, in such manner, and containing such information as the Secretary may require.
“(4) PRIORITY.—In awarding grants under this subsection, the Secretary may give priority, as appropriate, to eligible entities that have a relationship with a community-based organization that has experience in, or is capable of, providing services to individuals with heritable blood disorders, including sickle cell disease.
“(5) ELIGIBLE ENTITY.—In this subsection, the term ‘eligible entity’ includes the 50 States, the District of Columbia, the Commonwealth of Puerto Rico, the United States Virgin Islands, the Commonwealth of the Northern Mariana Islands, American Samoa, Guam, the Federated States of Micronesia, the Republic of Marshall Islands, the Republic of Palau, Indian tribes, a State or local health department, an institution of higher education, or a nonprofit entity with appropriate experience to conduct the activities under this subsection.”.
(1) by striking “Sickle Cell Disease” each place it appears and inserting “sickle cell disease”;
(2) in paragraph (1)(A), by striking “shall conduct a demonstration program by making grants to up to 40 eligible entities for each fiscal year in which the program is conducted under this section for the purpose of developing and establishing systemic mechanisms to improve the prevention and treatment of Sickle Cell Disease” and inserting “shall continue efforts, including by awarding grants, to develop or establish mechanisms to improve the treatment of sickle cell disease, and to improve the prevention and treatment of complications of sickle cell disease, in populations with a high proportion of individuals with sickle cell disease”;
(A) by striking clause (ii) (relating to priority); and
(B) by striking “Grant award requirements” and all that follows through “The Administrator shall” and inserting “Geographic diversity.—The Administrator shall”;
(4) in paragraph (2), by adding the following new subparagraph at the end:
“(E) To provide or coordinate services for adolescents with sickle cell disease making the transition to adult health care.”; and
(5) in paragraph (6), by striking “$10,000,000 for each of fiscal years 2005 through 2009” and inserting “$4,455,000 for each of fiscal years 2019 through 2023”.
(1) transferred to the Public Health Service Act (42 U.S.C. 201 et seq.);
(2) redesignated as subsection (b); and
(3) inserted at the end of section 1106 of such Act, as added by section 2 of this Act.
It is the Sense of the Senate that further research should be undertaken to expand the understanding of the causes of, and to find cures for, heritable blood disorders, including sickle cell disease.